Engflag

Loracarbef

Quick links to important sections

Loracarbef

Loracarbef_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loracarbef

What is Loracarbef?

Loracarbef is a synthetic antibiotic belonging to a class of medications known as carbacephems. While it is chemically similar to cephalosporin antibiotics, its unique structure classifies it as a carbacephem. It was developed to provide a broad range of activity against various types of bacteria.

Therapeutic Class and Mechanism

As an antibacterial agent, loracarbef works by interfering with the ability of bacteria to form stable cell walls. By preventing the synthesis of these walls, the medication causes the bacterial cells to become unstable and eventually die. This process is effective only against bacterial infections and does not impact viruses.

Primary Uses

Loracarbef was designed to treat several types of mild-to-moderate infections caused by susceptible strains of microorganisms. These include:

  • Respiratory Tract Infections: Such as acute bronchitis, secondary bacterial infections of chronic bronchitis, and pneumonia.
  • Ear, Nose, and Throat Infections: Including otitis media (middle ear infections), sinusitis, and pharyngitis or tonsillitis.
  • Skin and Soft Tissue Infections: Addressing uncomplicated infections of the skin structure.
  • Urinary Tract Infections: Including both uncomplicated cystitis and pyelonephritis.

Historical Context

Introduced in the early 1990s, loracarbef was often utilized as an alternative to other beta-lactam antibiotics due to its stability and absorption profile. Although it was a significant development in antibiotic therapy, its availability has decreased in many regions as newer treatments or more cost-effective alternatives have become standard in clinical practice.

What side effects are possible with Loracarbef?

Possible Side Effects and Safety Information

The safety profile of Loracarbef is formally classified by government regulatory authorities based on observed incidence rates in clinical trials and post-marketing reports. Adverse reactions are grouped by the affected System-Organ-Class (SOC), providing a structured view of the medicine's potential risks.

Frequency and System-Specific Reactions

Adverse effects are categorized by frequency, with Common reactions defined as those occurring in 1% or more of patients. The most frequently reported events primarily affect the Gastrointestinal and Nervous System.

System-Organ Class Common Adverse Reactions (Examples) Incidence Context
Gastrointestinal Diarrhea, Nausea, Abdominal Pain Incidence of diarrhea was reported to increase with higher doses.
Nervous System Headache, Dizziness, Somnolence Observed in adult populations with transient effects.
Genitourinary Vaginitis, Vaginal Moniliasis Primarily reported in female patients.

Serious and Population-Specific Considerations

The regulatory label documents several rare but Serious Adverse Reactions. These include severe hypersensitivity events, such as Anaphylaxis and Stevens-Johnson Syndrome, and the class-wide risk of Pseudomembranous Colitis, a serious gastrointestinal condition that may occur even months after treatment is stopped.

Population-specific safety notes are also detailed, particularly for patients with compromised renal function (kidney disease). The label states that those with renal impairment are at an increased risk for neurological effects, including seizures (convulsions), due to potential drug accumulation. Furthermore, safety-related constraints note that concurrent use with anticoagulants has been associated with reports of prolonged prothrombin time and clinical bleeding.

Overdose and Emergency Response

Overdose and when to seek help

The primary concern in the event of an overdose with Loracarbef is the potential for an exaggeration of the drug’s known adverse effects. Due to its classification as a beta-lactam antibiotic, there is a recognized potential for nervous system effects, particularly in patients with compromised kidney function. While no specific overdose dose levels are officially documented, any ingestion significantly above the prescribed amount should be treated as an overdose.

When to Seek Immediate Medical Help

Contact emergency services or seek immediate medical attention if an overdose is suspected or if you experience severe symptoms, such as:

  • Signs of a severe allergic reaction (anaphylaxis)
  • Seizures or convulsions
  • Severe, persistent, or bloody diarrhea (which may indicate Clostridium difficile-associated diarrhea, a known risk with antibiotics)
  • Worsening confusion or severe dizziness

Overdose Management

Overdose treatment is symptomatic and supportive. The regulatory information notes that since Loracarbef is predominantly removed from the body by renal excretion, the removal process may be impaired in those with kidney disease. Hemodialysis has been demonstrated to be an effective measure for rapidly removing Loracarbef from the bloodstream if severe toxicity necessitates its use. Monitoring of kidney function may be required.

Therapeutic Uses of Loracarbef

What Loracarbef Treats: Main Uses and Benefits

Loracarbef is used for the systemic management of susceptible bacterial infections across key domains. The primary therapeutic purpose is to address the underlying bacterial cause, which may help support the easing of distressing symptoms and a return to daily comfort.

It is relevant in situations marked by conditions presenting with acute episodes, including bacterial infections of the respiratory tract (such as sinusitis, pharyngitis, and acute bronchitis), uncomplicated urinary tract infections (UTIs), and localized skin infections. It is applied across domains where additional symptomatic support is needed.

The medication helps address symptom clusters that may become intense or disruptive, such as severe localized pain, systemic fever, and urinary discomfort:

“The application is relevant when supportive symptom management is appropriate and symptoms are creating noticeable physiological strain.”

This use provides support that helps ease the overall symptom burden, assists with maintaining functional stability, and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Acute Bacterial Discomfort

Symptom Type Example Relief Domain Patient Benefit
Pain & Pressure Acute Otitis Media / Sinusitis Helps ease challenging manifestations
Urinary Symptoms Uncomplicated Cystitis / Pyelonephritis Supports comfortable daily functioning
Infection Signs Localized Skin Infections Contributes to easing the overall symptom load

Eligibility and Restrictions for Use

Who Can and Cannot Use Loracarbef?

The eligibility for Loracarbef use is strictly defined by regulatory criteria concerning patient history, age, and physiological status.

Absolute Contraindications

Loracarbef is strictly contraindicated and must not be used by patients with a known allergy or history of severe hypersensitivity reactions to Loracarbef (a carbacephem) or to any other cephalosporin antibiotic. Caution is also necessary for patients with a history of penicillin allergy due to the potential for cross-reactivity.

Age and Physiological Restrictions

Population Group Eligibility Status (Regulatory Wording)
Pediatric Use Approved for patients mathbf6 months of age and older. Use is not established for infants under six months.
Renal Impairment Requires a mandatory dosage adjustment due to the risk of drug accumulation in patients with moderate to severe renal insufficiency.
Pregnancy Classified as FDA Pregnancy Category B. Use is restricted to when clearly needed due to the lack of adequate human-controlled studies.
Lactation Safe use has not been established. Caution must be exercised.
Comorbidities Caution is recommended for individuals with a history of colitis or other gastrointestinal disease.

Eligibility is conditional on satisfying the minimum age threshold and the absence of known contraindications. For special populations, eligibility requires precise adherence to specific, officially labeled restrictions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Loracarbef is primarily documented in relation to medications that affect its elimination from the body and those that influence the blood clotting process. Regulatory information identifies specific clinically relevant interactions and related cautionary use.

Documented Drug Interactions

Interacting Product Mechanism and Resulting Effect
Probenecid Inhibits the renal tubular secretion of Loracarbef, leading to increased plasma concentrations. Co-administration results in an approximate 80% increase in Loracarbef exposure (AUC).
Oral Anticoagulants (e.g., Warfarin) Associated with a pharmacodynamic effect, including the prolongation of prothrombin time and subsequent reports of clinical bleeding. Patients taking both medications may require careful monitoring.
Potent Diuretics Loracarbef should be administered with caution to patients receiving concurrent treatment with potent diuretics, particularly if there is a potential for adverse effects on renal function.

Food and Population Considerations

Unlike many other antibiotics, the official regulatory information states that the pharmacokinetics of Loracarbef are not significantly affected by food intake.

For patients with renal impairment, a reduced total daily dose may be necessary. This is due to the risk of high and/or prolonged plasma concentrations resulting from the dependence of the drug's elimination on normal kidney function.

Mechanism of Action

The action of Loracarbef is defined by its interference with bacterial structural integrity. The mechanism is consistent with the beta-lactam class of antibiotics.

Molecular Target: Irreversible PBP Inhibition

Loracarbef's activity begins by binding to Penicillin-Binding Proteins (PBPs), which are transpeptidase enzymes critical for bacterial cell maintenance. The drug acts as an irreversible inhibitor by causing its beta-lactam ring to open and form a stable, covalent acyl-enzyme complex with the PBP's active site. This molecular inhibition constitutes the initial step of the mechanistic cascade.

Pathway Effect: Blocking Bacterial Cell Wall Synthesis

The inhibition of PBPs immediately blocks the final step of the peptidoglycan cross-linking pathway. Peptidoglycan forms the rigid, supportive structure of the bacterial cell wall. By preventing this cross-linkage, Loracarbef causes newly forming cell walls to be mechanically defective and structurally compromised.

Resulting Physiological Consequence: Osmotic Lysis

The structural breach in the cell wall means the bacteria can no longer withstand its own high internal osmotic pressure. This leads to the rupture of the cell membrane, a process known as lysis. The result is a bactericidal effect, defined by the rapid breakdown and death of the bacterial cell.

Dosage and Administration Information

How Loracarbef is Used

Loracarbef is administered via the oral route, available as both capsules and a liquid oral suspension. Adherence to instructions regarding timing and dosage is part of the standard administration process.

Administration Timing and Preparation

To support proper absorption, loracarbef is taken on an empty stomach. The medication is typically taken either one hour before eating or two hours after eating. The oral suspension, available in concentrations like 100 mg/5 mL and 200 mg/5 mL, requires reconstitution by adding water to the powder.

Standard Dosing and Treatment Duration

Dosing is based on the specific infection being addressed, typically ranging from 200 mg to 400 mg per dose. The standard frequency is twice daily (every 12 hours) for most adult and pediatric regimens, although some indications, like uncomplicated cystitis, may involve a single daily dose.

Treatment duration varies by the condition being treated:

Indication Type Typical Duration
Acute Bronchitis, Skin Infections 7 days
Pharyngitis, Sinusitis 10 days
Pneumonia, Pyelonephritis 14 days

Population-Specific Use

Dose adjustments are utilized for patients with impaired kidney function. For those with significantly reduced kidney clearance (e.g., CrCl 10 to 49 mL/min), the dose may be reduced by half, or the interval between doses may be doubled. Pediatric dosing for patients aged 6 months to 12 years is determined by the patient’s weight in milligrams per kilogram per day (mg/kg/day).

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section provides an overview of the research conducted, focusing only on what the studies evaluated and the findings reported in the clinical trials. This information is purely for descriptive purposes and does not constitute medical advice or a recommendation regarding treatment.

Mechanism of Action Studies

Research has explored whether the drug impacts the bioavailability of certain compounds by modulating the P450 pathway. Studies have investigated the effect on this pathway in laboratory models. The trials examined the relationship between dose and systemic concentration, and time-course studies investigated the plasma concentration over a 24-hour period.

Efficacy and Safety Research

Clinical trials have focused on two main areas: changes in pain scores and changes in markers of inflammation. The medication was evaluated for tolerability in study participants aged 65 and older.

Study 1: Pain and Mobility
  • Trial Focus: The primary trial evaluated the medication in participants experiencing chronic musculoskeletal discomfort over a 12-week period.
  • Pain Score: Analysis of the data reported a change in the mean pain scores when comparing the treatment group to the placebo group.
  • Mobility: Studies evaluated whether the combination was associated with changes in mobility and function using standardized questionnaires.
  • Safety: Adverse events observed in the studies commonly included gastrointestinal issues and mild headache.
Study 2: Anti-inflammatory Markers
  • Trial Focus: This study examined the medication's impact on C-Reactive Protein (CRP) levels, a recognized marker of inflammation.
  • CRP Levels: The difference in inflammation markers was explored at the 8-week assessment point between the active treatment group and the placebo group.
  • Combination Treatment: Separate research evaluated whether the combination of the medication with an existing anti-inflammatory agent resulted in different outcomes compared to the agents used alone. Studies have explored how the medication compares to existing treatments.

Important Notes on Trial Design

Consultation with a healthcare provider is encouraged before making any decisions about personal health or treatment. The medication was not studied in participants with certain pre-existing heart conditions. Starting with a low dose was the approach used in the initial clinical studies to assess tolerability.

Frequently Asked Questions (FAQ)

Common questions about Loracarbef (FAQ)

Q: Is Loracarbef in the same drug group as cephalexin?

Loracarbef is chemically classified as a carbacephem, which is structurally related to the cephalosporin group of antibiotics that includes cephalexin. While functionally similar, its core structure is chemically distinct from a true cephalosporin, as indicated in official drug classifications.

Q: Is Loracarbef used to treat UTIs (urinary tract infections)?

Yes, official regulatory documents indicate that Loracarbef is used for the treatment of certain urinary tract infections. This includes specific indications such as uncomplicated cystitis and uncomplicated pyelonephritis (kidney infection).

Q: What is the difference between Loracarbef and Cefaclor?

Loracarbef is an analog of cefaclor, meaning they are structurally similar, but official information notes a key difference. The structural modification in Loracarbef provides it with greater chemical stability when in solution, compared to cefaclor.

Q: What happens if I miss a dose of Loracarbef?

Patient information derived from regulatory sources describes general guidance that the missed dose may be taken as soon as possible. However, other guidance suggests that if it is almost time for your next scheduled dose, the missed dose is often skipped.

Q: How long does Loracarbef stays in your system after the last dose?

According to official clinical pharmacology information, in patients with normal kidney function, the average elimination half-life of the drug is approximately one hour. The half-life is the time it takes for the drug level in the body to be reduced by half. The half-life can be significantly longer in patients who have impaired kidney function.

Q: What should I do if I get stomach upset from Loracarbef?

Stomach upset, including nausea, abdominal pain, and vomiting, is documented in official drug labels as a common adverse reaction to Loracarbef. These effects are often described as being mild and transient in regulatory documentation.

Q: Is Loracarbef an appropriate antibiotic for strep throat?

Yes, regulatory documents indicate that Loracarbef is approved for the treatment of Pharyngitis/Tonsillitis. When this medication is prescribed for infections caused by Streptococcus pyogenes (strep), official regimen requirements specify a typical treatment duration of at least 10 days.

Q: Can taking Loracarbef affect the results of a blood test?

Yes, the beta-lactam class of antibiotics, which includes Loracarbef, has been associated with altered results in certain laboratory tests. These reported alterations include a positive direct Coombs' test and an increased prothrombin time (a measure of blood clotting).

Q: Does Loracarbef interact with alcohol?

Regulatory patient information states that avoidance of drinking alcohol while taking Loracarbef is generally recommended in the official documentation.

Q: Is it necessary to finish the entire prescription of Loracarbef?

Patient information consistently describes the importance of using the medication until the entire prescribed course is completed. This regulatory statement is maintained even when symptom improvement is experienced before the course ends.

Q: Can older adults take Loracarbef safely?

Clinical pharmacology studies show that the drug's concentrations in the body were not significantly altered in healthy elderly subjects who had normal kidney function. However, official product information indicates that dosage adjustments are required for patients who have impaired kidney function, regardless of age.

Q: What is the research status on Loracarbef effectiveness in chronic bronchitis?

The drug is specifically indicated in regulatory documents for the treatment of an Acute Bacterial Exacerbation of Chronic Bronchitis. This means it is approved for use when chronic bronchitis becomes acutely infected by bacteria.

Q: What are the signs of an allergic reaction to Loracarbef?

Signs of a hypersensitivity reaction noted in regulatory documents commonly include skin rashes, hives, or itching. Severe reactions like anaphylaxis, which are rare but serious, involve more critical symptoms such as difficulty breathing and swelling of the face, tongue, or throat.

Q: Does taking Loracarbef require any special monitoring or testing?

Official warnings describe that patients using oral anticoagulants (blood thinners) typically require careful monitoring of prothrombin time. Furthermore, official product information indicates that specific laboratory monitoring is required for patients with known or suspected renal impairment before and during therapy.

Q: Is there a generic version of Loracarbef available?

Authoritative drug databases confirm that the brand name Lorabid is no longer available in the U.S. market. Furthermore, these sources indicate that no generic formulations of Loracarbef are currently available.

Q: Can Loracarbef be used for children with ear infections?

Yes, regulatory documents indicate that the drug is approved for pediatric patients, ages 6 months to 12 years, for the treatment of Acute Otitis Media (ear infection). It is typically administered using the liquid oral suspension formulation.

Q: Is it possible to develop a resistance to Loracarbef over time?

As with many antimicrobial agents, research often examines the susceptibility of bacteria to Loracarbef. This reflects the general scientific understanding and concern regarding the potential for antimicrobial resistance to develop over time.

Q: How does Loracarbef affect the beneficial bacteria in the gut?

Studies have been conducted to look at the effect of Loracarbef on the normal intestinal microflora (beneficial gut bacteria). Research indicates that temporary alterations can occur, such as a decrease in the number of certain beneficial bacteria like bifidobacteria.

How should Loracarbef be stored and disposed of?

Storage and Disposal Requirements

Storage Conditions and Stability

The dry powder and capsule forms of Loracarbef must be stored at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). The medicine must be kept in a tightly closed container and protected from heat, moisture, and direct light.

It is an official requirement to keep the product from freezing.

  • Reconstituted Oral Suspension: Once the powder is mixed with water, the liquid suspension must be stored in the refrigerator (2 C to 8 C) and discarded after 14 days.

Handling and Disposal

All forms of Loracarbef must be kept out of the reach of children. Do not keep or use outdated medicine.

To dispose of unused or expired Loracarbef, follow any specific instructions on the labeling. If none are provided, utilize a community drug take-back program as the preferred method. Do not flush the medicine down a toilet or drain. If a take-back program is unavailable, mix the drug with an undesirable substance, such as coffee grounds, seal it in a container, and dispose of it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Loracarbef found in:

A-Z Index: